AstraZeneca (LON:AZN – Get Rating)‘s stock had its “overweight” rating reissued by equities research analysts at JPMorgan Chase & Co. in a research note issued to investors on Thursday, MarketBeat.com reports. They currently have a £120 ($145.31) price target on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 9.03% from the company’s current price.
AZN has been the topic of several other reports. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research report on Tuesday, June 28th. Credit Suisse Group set a £110 ($133.20) target price on shares of AstraZeneca in a research note on Tuesday, June 7th. Citigroup restated a “buy” rating and set a £105 ($127.15) target price on shares of AstraZeneca in a research note on Wednesday, June 22nd. Jefferies Financial Group set a GBX 9,500 ($115.04) target price on shares of AstraZeneca in a research note on Friday, April 29th. Finally, Deutsche Bank Rese… set a £115 ($139.26) target price on shares of AstraZeneca in a research note on Tuesday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of £105.46 ($127.70).
Lithium is the uncontested fuel of the green energy revolution. One little-known small-cap lithium mining company in a renowned South American location has started attracting interest from opportunity-minded investors.
AZN stock traded up GBX 28 ($0.34) during trading on Thursday, hitting £110.06 ($133.28). 1,887,321 shares of the stock traded hands, compared to its average volume of 2,285,388. AstraZeneca has a 1 year low of GBX 8,029 ($97.23) and a 1 year high of £111.70 ($135.26). The firm’s 50 day moving average is £103.95 and its two-hundred day moving average is GBX 9,619.27. The stock has a market cap of £170.54 billion and a price-to-earnings ratio of -187.18. The company has a debt-to-equity ratio of 90.06, a current ratio of 1.00 and a quick ratio of 0.65.
AstraZeneca Company Profile (Get Rating)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
Should you invest $1,000 in AstraZeneca right now?
Before you consider AstraZeneca, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and AstraZeneca wasn’t on the list.
While AstraZeneca currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Leave a Comment